Article
Adoptive T‐cell transfer in cancer immunotherapy
2 May 2006
Abstract excerpt
Adoptive T-cell therapy has definite clinical benefit in relapsed leukaemia after allogeneic transplant and in Epstein-Barr virus-associated post-transplant lymphoproliferative disease. However, the majority of tumour targets are weakly immunogenic self-antigens and success has been limited in part by inadequate persistence and expansion of transferred T cells and by tumour-evasion strategies. Adoptive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
